Home Featured Page 267

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Small Pharma Inc. to Commence Trading on the TSX Venture Exchange...

Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural...

Lobe Sciences Acquires Vitamind Line of Wellness Products

PT242 – Gary Laderman – Religion: Sex, Death, and Drugs

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in...

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration...

Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces...

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.